Evidence map›Paper›PMID 42059970›Full record

ReviewWorld journal of urology2026

Management of lower urinary tract symptoms before prostate cancer radiotherapy: a call for innovative strategies.

Jennifer Le Guevelou, Julien Anract, Charles Dariane, Matthijs Scheltema, Rui Bernardino, Lorenzo Bianchi, Veeru Kasivisvanathan, Mattia Sibona, Andrea Mari, Marc Sapoval and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jennifer Le GuevelouUniversity of medicine François Rabelais, Tours, France. Jennifer.leguevelou@gmail.com.
Julien AnractDepartment of Urology, AP-HP, Hôpital Cochin, Université Paris Cité, Paris, France.
Charles DarianeDepartment of Urology, Hôpital Européen Georges Pompidou, AP-AP, Paris, France.
Matthijs ScheltemaSt. Antonius Hospital, Utrecht, The Netherlands.
Rui BernardinoGlickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Lorenzo BianchiDivision of Urology, IRCCS Azienza Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Veeru KasivisvanathanCentre for Urology Imaging, Prostate, AI and Surgical Studies (COMPASS) Research Group, Division of Surgery and Interventional Science, University College London, London, UK.
Mattia SibonaCittà della Salute e della Scienza e Università degli Studi di Torino, Torino, Italy.
Andrea MariOncologic Minimally Invasive Urology and Andrology Unit, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, 50121, Italy.
Marc SapovalDepartment of Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, 75015, France.
Marcin MiszczykDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Pawel RajwaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Tom BoekenDepartment of Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, 75015, France.
Giancarlo MarraCittà della Salute e della Scienza e Università degli Studi di Torino, Torino, Italy.
YAU Prostate Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Benign prostatic hyperplasia (BPH) is the main cause of lower urinary tract symptoms (LUTS) in aging men. As the incidence of prostate cancer (PCa) increases with age, coexistence of BPO and PCa is a frequent issue. Radical prostatectomy might be considered as the best option for patients presenting with severe obstructive symptoms, allowing to simultaneously treat both diseases. However, not all patients are eligible or prefer surgery, therefore a large number of patients are referred to receive PCa radiotherapy (RT). Preexisting LUTS represent a well-known risk factor to develop severe genito-urinary (GU) toxicity. While improving urinary function before starting irradiation appears to be crucial, the development of new minimally invasive surgical therapies (MIST) for BPH creates new opportunities for treatment personalization in RT patients with LUTS.

Indexed as

Lower Urinary Tract SymptomsProstatic HyperplasiaProstatic NeoplasmsHumansMaleProstatectomyLower urinary tract symptomsMinimally-invasive surgical treatmentProstate cancerRadiotherapyTransurethral resection of the prostate

Identifiers

PMID42059970
PMCPMC13132912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.